secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2022-11-22T23:59:59+00:00
Accession:  0001140361-22-042770
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics restructures license with Factor Bioscience, gains right to sublicense three US patents
--------------------------------------------------------------------------------

- Amendment dated Nov 22, 2022 grants exclusive sublicensing rights to three US patents (10,662,410, 10,829,738, 10,982,229) from Factor to Brooklyn Immunotherapeutics.
- Prior Novellus-Factor license terminated; Novellus removed and Factor becomes direct licensor to Brooklyn and NoveCite (25% owned by Eterna).
- Brooklyn pays Factor 20% of sublicense fees (first 5-year term) and 30% (potential 2.5-year extension); extension contingent on $100M in sublicense fees.
- License term is 5 years, extendable by 2.5 years; Eterna guarantees all payments and obligations of Brooklyn under the amended agreement.
- Dr. Matthew Angel, Eterna's interim CEO, is co-founder, President, and CEO of Factor Bioscience's parent; transaction is a related-party deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036122042770/0001140361-22-042770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036122042770/brhc10044587_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-042770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer